==== Front
Pilot Feasibility Stud
Pilot Feasibility Stud
Pilot and Feasibility Studies
2055-5784
BioMed Central London

1347
10.1186/s40814-023-01347-6
Correction
Correction: Development, implementation, and feasibility of site‑specific hepatitis C virus treatment workflows for treating vulnerable, high‑risk populations: protocol of the Erase Hep C study — a prospective single‑arm intervention trial
Desai Anmol 1
O’Neal Lauren 2
Reinis Kia 1
Chang Patrick 1
Brown Cristal 34
Stefanowicz Michael 14
Kuang Audrey 134
Agrawal Deepak 3
Bhavnani Darlene 1
Mercer Tim tim.mercer@austin.utexas.edu

134
1 grid.89336.37 0000 0004 1936 9924 Department of Population Health, The University of Texas at Austin Dell Medical School, Austin, USA
2 grid.89336.37 0000 0004 1936 9924 The University of Texas at Austin Dell Medical School, Austin, USA
3 grid.89336.37 0000 0004 1936 9924 Department of Internal Medicine, The University of Texas at Austin Dell Medical School, Austin, USA
4 CommUnityCare Health Centers, Austin, USA
30 6 2023
30 6 2023
2023
9 108© The Author(s) 2023
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2023
==== Body
pmc Correction: Pilot Feasibility Stud 9, 78 (2023)

https://doi.org/10.1186/s40814-023-01311-4

Following publication of the original article [1], the authors identified an error in Table 2. The correct table is given below.Table 2 Erase Hep C study SPIRIT figure

	Screen	Enrollment	Treatment	
Start	End (Glecaprevir /Pibrentasvir)	End (Sofosbuvir /Velpatasvir)	SVR12 (Glecaprevir /Pibrentasvir)	SVR12 (Sofosbuvir /Velpatasvir)	
TIMEPOINT	T-1	T0	T1 = up to 90 days after T0	T2 = T1 + 60 days	T3 = T1 + 90 days	T4 = T2 + (90–120 days)	T5 = T3 + (90–120 days)	
ENROLLMENT:	
 Eligibility Screen	X							
 Informed Consent		X						
 Interview		X		X	X			
 Obtain EMR Data	X	X	X	X	X	X	X	
INTERVENTION:	
 Implement Site-Specific HCV Treatment Workflows		X	X	X	X	X	X	
ASSESSMENTS:	
 Demographic Variables		X		X	X			
 Socioeconomic Variables		X		X	X			
 Substance Use Variables		X		X	X			
 Sexual Behavior Variables				X	X			
 Medical History		X		X	X			
 Labs	X	X		X	X			
 SVR12						X	X	
 2º Clinical Outcomes			X	X	X	X	X	
 2º Implementation Outcomes			X	X	X	X	X	

The original article [1] has been updated.
==== Refs
Reference

1. Desai A O’Neal L Reinis K Development, implementation, and feasibility of site-specific hepatitis C virus treatment workflows for treating vulnerable, high-risk populations: protocol of the Erase Hep C study — a prospective single-arm intervention trial Pilot Feasibility Stud 2023 9 78 10.1186/s40814-023-01311-4 37158965